Gene Therapy Market Set to Surge to USD 38.33 Billion by 2030, Fueled by 22.2% CAGR”

Richmond, United States, 2024-Apr-04 — /EPR Network/ —

In 2023, the Gene Therapy Market was valued at USD 9.42 billion. It is projected to reach USD 38.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.2% during the forecast period from 2023 to 2030.

In the realm of medical science, gene therapy stands as a beacon of hope, offering revolutionary treatments for previously incurable genetic disorders. This blog delves into the dynamic landscape of the gene therapy market, exploring its evolution, key players, therapeutic applications, and future prospects in transforming healthcare.

Request free Sample: 

Major vendors in the global gene therapy market  :

  • Regenxbio, Inc.
  • Oxford BioMedica plc
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Applied Genetic Technologies Corporation
  • F. Hoffmann-La Roche Ltd
  • Bluebird Bio, Inc.
  • Novartis AG
  • Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
  • UniQure N.V.
  • Shire Plc
  • Cellectis S.A.
  • Sangamo Therapeutics, Inc.
  • Orchard Therapeutics
  • Gilead Lifesciences, Inc.
  • Sibiono GeneTech Co., Ltd
  • Shanghai Sunway Biotech Co., Ltd.
  • Gensight Biologics S.A.
  • Transgene
  • Calimmune, Inc.
  • Epeius Biotechnologies Corp.
  • Astellas Pharma Inc.
  • American Gene Technologies
  • BioMarin Pharmaceuticals Inc.
  • Others

Market Trends and Drivers:

  • Breakthrough Treatments: Recent advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc-finger nucleases, have paved the way for the development of novel gene therapies targeting a spectrum of diseases, including rare genetic disorders, cancer, and neurodegenerative diseases.
  • Regulatory Support: Regulatory agencies, such as the FDA and EMA, have granted accelerated approvals and orphan drug designations to several gene therapy products, expediting their market entry and encouraging investment in research and development.
  • Rising Investment: Increasing investments from biopharmaceutical companies, venture capitalists, and government initiatives have fueled the growth of the gene therapy market, driving innovation and expanding therapeutic pipelines.
  • Growing Demand: With a rising prevalence of genetic diseases, coupled with the unmet medical needs of patients, there is a growing demand for effective and curative treatments, positioning gene therapy as a promising solution in the healthcare landscape.

Request for Discount : 

Segmentations Analysis of Gene Therapy Market: –

  • By Technology
    • Viral Vector-Based Gene Therapy
      • Adeno-Associated Virus (AAV)
      • Lentivirus
      • Adenovirus
      • Retrovirus
      • Modified Herpes Simplex Virus
    • Non-Viral Vectors-Based Gene Therapy
      • Electroporation
      • Gene Gun
      • Liposomes
      • Naked DNA
    • CRISPR/Cas9 Technology
  • By Therapy Type
    • Acute Lymphoblastic Leukemia (ALL)
    • Inherited Retinal Disease
    • Large B-Cell Lymphoma
    • ADA-SCID
    • Melanoma (lesions)
    • Beta-Thalassemia Major/SCD
    • Head & Neck Squamous Cell Carcinoma
    • Peripheral Arterial Disease
    • Spinal Muscular Atrophy (SMA)
    • Others
  • By Therapeutic Area
    • Oncology
    • Neurological Disorders
    • Genetic Disorders
    • Cardiovascular Disorders
    • Ophthalmic Disorders
  • By End User
    • Hospitals and Clinics
    • Biopharmaceutical Companies
    • Research Institutes
  • By Region
    • North America
      • US
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
      • Chile
      • Peru
      • Rest of Latin America
    • Europe
      • Germany
      • France
      • Italy
      • Spain
      • U.K.
      • BENELUX
      • CIS & Russia
      • Nordics
      • Austria
      • Poland
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Thailand
      • Indonesia
      • Malaysia
      • Vietnam
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa
      • Nigeria
      • Egypt
      • Israel
      • Turkey
      • Rest of MEA

Key Market Players:

  • Novartis AG
  • Spark Therapeutics (a Roche company)
  • Bluebird Bio, Inc.
  • Gilead Sciences, Inc. (through its acquisition of Kite Pharma)
  • Biogen Inc.
  • Pfizer Inc.

Therapeutic Applications: Gene therapy holds immense potential across various therapeutic areas, including:

  • Rders: Leber congenital amaurosis (LCA), retinitis pigmentosa, age-related macular degeneration (AMD).

Future Outlook: The gene therapy market is poised for significant growth, driven by ongoing research and development efforts, technological innovations, and increasing adoption of personalized medicine approaches. As more gene therapies progress through clinical trials and gain regulatory approvals, the market is expected to witness substantial expansion and diversification in the coming years.

Buy Now market report: 

Conclusion: Gene therapy represents a paradigm shift in the treatment of genetic diseases, offering hope for patients with previously untreatable conditions. With its potential to provide curative treatments, improve patient outcomes, and revolutionize healthcare, gene therapy stands at the forefront of medical innovation. As the field continues to evolve, collaboration between researchers, industry stakeholders, and regulatory agencies will be crucial in unlocking the full potential of gene therapy and ushering in a new era of precision medicine.

Contact Us:
1248 CarMia Way Richmond,
VA 23235, United States.
Phone: +1 510-730-3200

Matched content

Editor’s pick

Express Press Release Distribution